Table 2 Characteristics of subjects stratified by percentage of eosinophils and neutrophils in sputum
From: CXC chemokine superfamily induced by Interferon-γ in asthma: a cross-sectional observational study
Paucigranulocytic | Eosinophil-predominant or Neutrophil-predominant | Mixed granulocytic | Healthy Subjects | Overall | |
|---|---|---|---|---|---|
P value* | |||||
Subjects, n (%) | 9 (23) | 22 (56) | 8 (21) | 12 | |
Eos dominant/Neu dominant, n (%) | N. A. | 19/3 (86/14) | N. A. | N. A. | |
Age, y | 50 (20–71) | 58 (30–71) | 55 (22–72) | 47 (30–57) | N. S. |
Male/female, n (Male, %) | 3 (33)/6 | 9 (41)/13 | 4 (50)/4 | 4 (33)/8 | N. S. |
BMI | 24.5 (6.1) | 21.8 (2.5) | 21.9 (1.0) | 22.1 (3.1) | N. S. |
Duration of asthma (y) | 5.1 (5.6) | 10.8 (9.7) | 23.4 (20.5)† | N. A. | 0.01 |
Ex-smokers, n (%) | 4 (44) | 9 (41) | 1 (12) | 0 (0) | 0.03 |
Non-severe/Severe, n (Severe, %) | 6/1 (11) | 14/8 (36) | 6/2 (25) | N. A. | N. S. |
Medication | |||||
ICS dose (μg/day) | 900 (500–1150) | 800 (400–1150) | 800 (400–1200) | N. A. | N. S. |
LABA, n (%) | 6 (67) | 12 (55) | 7 (88) | N. A. | N. S. |
LTRA/TP, n (%) | 6 (67)/3 (33) | 13 (59)/11 (50) | 7 (88)/4 (50) | N. A. | N. S. |
Oral corticosteroids, n (%) | 0 (0) | 4 (18) | 1 (13) | N. A. | N. S. |
Atopy, n (%) | 5 (57) | 14 (64) | 6 (75) | 5 (42) | N. S. |
Asthma control and health care use, past year | |||||
β-agonist use/day | 0.00 (0.00–0.01) | 0.00 (0.00–0.02) | 0.00 (0.00–0.68) | N. A. | N. S. |
Oral Corticosteroid bursts | 1.0 (1.0–2.5) | 1.0 (0.0–1.0) | 1.0 (0.0–2.0) | N. A. | N. S. |
FEV1, L/min | 2.3 (0.6) | 2.1 (0.9)‡ | 2.0 (1.0)§ | 3.2 (0.8) | 0.05 |
FEV1, % predicted | 89.7 (14.9) | 81.3 (22.4)װ | 72.9 (18.2)¶ | 105.5 (14.6) | 0.01 |
FeNO, ppb | 18.5 (12.3–45.5) | 34.5 (13.3–51.0) | 53.2 (21.5–99.0) | N.D. | N. S. |